Stock code: 000710 Securities abbreviation: Berry Gene Announcement number: 2021-070
The Company and all members of the Board of Directors warrant that the information disclosed is true, accurate and complete and that there are no misrepresentations, misleading statements or material omissions.
Hangzhou Berry Hekang Gene Diagnostic Technology Co., Ltd., a wholly-owned subsidiary of Chengdu Berry Hekang Gene Technology Co., Ltd. (hereinafter referred to as the "Company"), recently received the medical device registration inspection report issued by the Medical Device Quality Supervision and Inspection Center:
Sequencing technology provides high accuracy, ultra-long reading, uniform coverage, and the ability to directly detect base modifications, and through SMRT sequencing technology, it is possible to screen for certain major diseases that are not within the detection range of high-throughput sequencing technology (NGS).
The II CNDx gene sequencer currently only passes the technical requirements test, and the company will declare medical device registration for this product. In the future, if the product is approved for listing, it will help the company achieve full coverage of the hardware platform of medium and high-throughput second-generation gene sequencers and third-generation gene sequencers, and strengthen the company's strategic layout in the upstream field of gene sequencing.
There is still uncertainty about the approval of the medical device registration of the above products, and the company is unable to predict the impact on the company's future performance. The company will fulfill the information disclosure obligation in a timely manner according to the progress of the registration of medical devices of the above products, and please pay attention to the investment risks of the majority of investors.
This is hereby announced.
Chengdu Berry and Kang Gene Technology Co., Ltd
board of directors
October 26, 2021